While physiological levels of glucocorticoids are required to ensure proper functions of the body, consistently high levels may engender several deleterious consequences.
| INTRODUCTION
Glucocorticoids (GCs) exert essential roles on several aspects of normal cellular and physiological processes. In addition to their effects on glucose metabolism, GCs affect cell survival, proliferation, reproduction, growth, cognition, and behavior, also exerting regulatory effects on the cardiovascular, the immune, and the central nervous systems. 1, 2 GCs, final effectors in the stress response, are synthesized and released by the adrenal cortex after binding of pituitary ACTH to specific melanocortin-2 receptors and activation of a downstream signaling pathway. ACTH is, in turn, a proteolytic processing product of the prohormone proopiomelanocortin (POMC), whose synthesis is induced by the hypothalamic peptides corticotropin-releasing hormone (CRH) and arginine-vasopressin, upon activation of upper levels of the central nervous system. Sustained excessive GC levels, as those present in patients with Cushing's syndrome, are associated with an increase in morbidity and mortality due to cardiovascular, thrombotic, metabolic, infectious, and musculoskeletal complications. 3, 4 Hypercortisolism has been ascribed in many of these patients to increased ACTH production by pituitary ACTH-secreting tumors. 6, 7 Patients with hypercortisolism present with many of the characteristics of the metabolic syndrome, among them, visceral fat deposition, hyperglycemia, higher levels of plasma non-esterified free fatty acids, obesity, and insulin resistance (IR). 8, 9 In fact, a role for GCs in the development and maintenance of obesity and IR syndrome has been suggested. 12 , 13 Recently, we have demonstrated that the administration of a sucrose-rich diet to Wistar rats (30% sucrose in the drinking water, SRD) stimulates the activity of the hypothalamic-pituitary-adrenal (HPA) axis and induces insulin resistance (IR) after 7 weeks of treatment.
14 Processing a high metabolic load, as in rats fed SRD, involves the generation of oxidative stress and inflammation as reported in adipose tissue and liver. 15, 16 Moreover, the activity of the HPA axis has been shown to be modulated by reactive oxygen species (ROS) and cytokines. 17, 18 In particular, increased ACTH production by pituitary corticotroph cells incubated with cytokines 24 or supraphysiological glucose concentrations through a ROS-dependent mechanism has been demonstrated. 25 Melatonin (5 methoxy-N-acetyltryptamine), the hormone mainly produced by the pineal gland is a multitasking molecule involved in multiple aspects of the physiological regulation of body functions such as circadian rhythms, immune responsiveness and reproductive activity in seasonally reproductive animals. 26, 27 A large body of evidence indicates that melatonin is also a major scavenger of oxygen-and nitrogen-based reactive molecules at both physiologic and pharmacologic concentration. 30, 31 Moreover, several intracellular enzymatic antioxidant enzymes, including superoxide dismutase, and glutathione peroxidase, among others, are stimulated by melatonin. 32, 33 In addition to these many antioxidant properties, different lines of evidence demonstrate melatonin anti-inflammatory properties, such as a decrease in cytokine production and nitric oxide synthase-2 inhibition. 35, 36 In the present study, we analyzed the effect of SRD on the HPA axis activity at early stages of treatment (ie, before the occurrence of IR). Moreover, since oxidant and inflammatory mechanisms could be involved in the effects of SRD on the synthesis and release of ACTH at pituitary level, we analyzed whether melatonin is able to abate HPA axis alterations.
| MATERIALS AND METHODS

| Animals
Adult male Wistar rats (200-250 g) were housed in groups (3 animals/cage) and maintained under controlled conditions of humidity and temperature (21 ± 2°C) under a 12 hours light-dark cycle. Rats were fed a standard chow diet ad libitum and either tap water (Control group) or 30% sucrose in tap water (30% w/v, SRD groups). All protocols were approved by the Animal Care and Use Committee (CICUAL) from Facultad de Medicina, Universidad de Buenos Aires and followed the "Principles of laboratory animal care" (NIH publication no. 85-23, revised 1985).
| Melatonin treatment
At the beginning of the experimental period indicated groups were implanted with a subcutaneous pellet of melatonin (20 mg with 3% w/v vegetable oil, compressed in a cylinder of 2.5 mm diameter and 1 mm length), while other groups were sham-operated without pellet implantation. The pellet of melatonin was implanted subcutaneously under the skin of the neck, and was replaced at mid-treatment. 37 Melatonin was obtained from Sigma Chemical Co. (St Louis, MO, USA).
| Tissue and serum samples
Animals were sacrificed by decapitation, between 9 am and 10 am, in order to minimize circadian variation among groups and trunk blood was collected. Anterior pituitary glands were dissected on ice and tissues were homogenized in 50 mmol/L Na 2 HPO 4 pH 7.4, 0.2 mmol/L EDTA, 100 mmol/L KCl, 1× protease inhibitor cocktail (Sigma Aldrich, CABA, Argentina), or in TRI® reagent (Genbiotech, CABA, Argentina) for total RNA isolation.
| Biochemical and hormonal measurements
Corticosterone levels were determined in serum samples by RIA after dichloromethane extraction, as described previously. 
| Immunohistochemistry
Animals were anesthetized with a ketamine and xylazine cocktail (50 mg/kg and 2 mg/kg respectively) and intracardially perfused with 4% paraformaldehyde in 0.1 mol/L sodium phosphate buffer pH 7.4. Pituitary tissues were dissected, postfixed in the same fixative for 12 h and dehydrated by incubating with solutions of increasing ethanol concentration (70%, 90%, and 100% v/v). Tissues were clarified with N-butyl acetate and embedded in paraffin (Biopack, CABA, Argentina). Pituitary glands were serially sliced in 4 µm sections using a rotating microtome (RM2125 RTS, Leica, Germany) with every section collected on charged slides and then dehydrated by heat (50°C for 10 min). After deparaffinization and rehydration, antigen retrieval was performed by incubating the sections in citrate buffer (10 mmol/L sodium citrate, 0.05% Tween-20 pH 6.3) for 30 min at 100°C. Tissue permeabilization was induced by incubating the sections with 0.3% Triton X-100 in 1× PBS. After three washes with 1× PBS sections were incubated for 1 hour in a blocking solution (2% normal horse serum).
Immunodetection was performed with rabbit anti-ACTH (1:1000, Santa Cruz Biotechnology, Dallas, TX, USA, Cat# sc-52980, RRID: AB_831670) or anti-Iba-1 (1:500, Abcam, Cambridge, MA, USA, Cat# ab5076, RRID: AB_2224402) in 1× PBS, overnight at 4°C in a humid chamber. For secondary detection, sections were incubated for 2 hours at room temperature in a dark chamber with fluorescent-dye conjugated secondary antibodies (Abcam Cat# ab150129, RRID: AB_2687506). Slides were mounted with fluorescence media with DAPI (Vectashield, Vector Laboratories, Burlingame, CA, USA) and images were acquired in a fluorescence microscope (BX-50 Olympus, Tokyo, Japan), through an incorporated digital camera (3CCD, Sony, Tokyo, Japan) and processed with Image J software (NIH, Bethesda, MD, USA). The number of Iba-1 positive cells was counted in an area of 500 x 500 pixels (12 images per treatment).
| Reverse transcription and quantitative real time polymerase chain reaction (RTqPCR) assays
Reverse transcription was performed using MMLV reverse transcriptase (Life Technologies, Argentina) as previously described. 41 Amplifications by qPCR were carried out in a RotorGene 6000 Corbett Life Science Real Time Thermal Cycler (Corbett Research, Sidney, NSW, Australia) and quantified with the Rotor Gene 6000 Series Software (version 1.7 Build 40, Hilden, Germany). Primer oligonucleotide sequences used in this study are listed in Supporting information Table S1 . Gene expression levels were normalized to Actb (β-Actin) as an internal control, using the ΔΔCt relative quantification method. Quant Imaging System (GE Healthcare, Chicago, IL, USA) and quantification was performed using Image J software (NIH, Bethesda, MD, USA).
| Cell lines and culture conditions
The mouse ACTH-secreting pituitary adenoma cell line, AtT-20/D16v-F2 (named AtT-20 hereafter) 44 was obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). AtT-20 cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM-Thermo Fisher Scientific, CABA, Argentina) supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 100 U/ml penicillin, 100 μg/ml streptomycin at 37°C and 5% CO 2 . All treatments were performed in serum-free DMEM.
Mouse macrophage-like cells, J774.1, were kindly provided by Dr Alejandra Goldman (Universidad Nacional de San Martín, Argentina) and maintained in DMEM medium supplemented with 100 U/mL of penicillin, 100 μg/mL of streptomycin, 100 U/ml amphotericin B and 10% FBS at 37°C and 5% CO 2 . J774.1 cells were incubated in the presence or absence of 100 ng/ml LPS (Escherichia coli endotoxin, serotype O111:B4) and 7.5 mmol/L d-glucose and 50 nmol/L melatonin. After 6 hours, the cells were washed three times with PBS, and the medium was replaced with complete culture medium. After culturing the cells for another 24 hours the conditioned media were collected, centrifuged at 1950 g for 20 min, and then filtered through 0.22-μm-pore filters (Millipore, Billerica, MA, USA) to remove cells and debris.
Cell viability, assessed by the Trypan-blue exclusion method, was calculated as % ratio of viable cells (unstained) to total cells. None of the treatments described in this study affected cell viability assessed by Trypan-blue exclusion method.
| Transfections and reporter assays
AtT-20 cells were seeded in 96-well plates (10 4 
| Statistical analysis
Data are presented as mean ± SE of the mean. Differences between the groups were analyzed by two-tailed unpaired Student's t test or by one-way ANOVA, as appropriate. When the ANOVA yielded significant differences (P < 0.05), post hoc comparisons (Tukey's tests) were made to determine the statistical difference between groups. All calculations were performed using Prism 7 for Mac OSX Version 7.0a (GraphPad Software, CA, USA).
| RESULTS
| Early functional changes in pituitary
glands from SRD-treated animals Figure 1 shows significantly higher systemic levels of ACTH and corticosterone after a short treatment with SRD ( Figure  1A and 1, respectively) compared to controls. Accordingly, increased levels of Pomc mRNA ( Figure 1C ) and ACTH protein ( Figure 1D ) were detected in pituitary tissues from SRD-treated rats. Interestingly, after three weeks of SRD a significant decrease in nocturnal serum melatonin levels was detected (Control: 160.7 ± 18.2 pg/ml n = 4, SRD: 98.9 8.2 pg/ml n = 6 P = 0.0081). As shown in Figure 2 , three weeks of treatment with SRD induced an increase in pituitary TBARS levels (Figure Figure 2B ), hemoxygenase-1 (HO-1) expression levels ( Figure 2C ) and nitrotyrosine-modified protein immunoreactivity (data not shown). In addition, an immunohistochemical analysis indicated a significantly higher number of Iba-1 (+) cells in the pituitary glands obtained from SRD-treated rats ( Figure 2D ). An increase in the protein levels of F4/80, a macrophage marker ( Figure 2E ), in mRNA levels of Il1b and the inflammasome components Asc and Nalp3 ( Figure 2F ) and in the mRNA levels of Tnfa (data not shown) were also observed in this group. Table 1 shows that rats fed a SRD for three weeks exhibited significantly higher fasting serum levels of glucose, non-esterified fatty acids (NEFA), and TAG, without significant differences in body weights compared to the corresponding controls. The administration of melatonin did not affect these parameters either in control or in SRD-treated rats.
| Preventive effects of melatonin treatment on SRD-induced pituitary dysfunction
Melatonin treatment prevented the SRD-dependent increase in pituitary lipid peroxides (Figure 2A ), catalase activity ( Figure 2B ) and HO-1 ( Figure 2C ) protein levels. In addition, melatonin also blocked the increase in Iba-1-immunoreactivity ( Figure 2D ) and F4/80-protein levels ( Figure  2E ) in pituitary glands from SRD-treated rats. The SRD-dependent increase in the pituitary expression of Il1b and the inflammasome components Asc, Nalp3, was also prevented by melatonin ( Figure 2F ). In addition, melatonin treatment suppressed the SRD-induced increase in ACTH protein levels ( Figure 3A ) as well as in systemic levels of ACTH ( Figure  3B ) and corticosterone ( Figure 3C ). 
| Effects of melatonin on the immuneendocrine interactions that lead to increased POMC/ACTH expression in AtT-20 cells
In order to test whether inflammatory mediators could contribute to the induction of Pomc, we treated corticotroph cells (AtT-20) with conditioned media (CM) obtained from mouse J774 macrophages stimulated with LPS (100 ng/ml) and/or moderately high glucose levels (D-Glu, 7.5 mM) in the presence or absence of melatonin (50 nmol/L) ( Figure  4A ). This treatment resulted in a seven-fold increase in Il1b levels in J774 cells (data not shown). As indicated in Figure  4B and C, when AtT-20 cells were incubated with CM obtained from macrophages stimulated with LPS + GLU, luciferase activity of the reporter plasmids pκB-Luc ( Figure 4B ) and POMC-pGL3 ( Figure 4C ) was significantly increased. Similar results were obtained by analyzing ACTH expression levels by immunoblot ( Figure 4D ). These effects were not observed when CM was obtained from macrophages stimulated with LPS + Glu in the presence of melatonin ( Figure 4B-D) .
| DISCUSSION
Our results indicate that a short-term SRD administration (3 weeks) induced significant changes in the activity of the HPA axis including an increase in systemic ACTH and corticosterone concentrations that correlated with elevated levels of Pomc and ACTH at the pituitary level. In addition, the occurrence of oxidative stress and inflammation was detected in the adenohypophysis of these animals. Present results also indicate that a treatment with melatonin prevented the SRDdependent induction of oxidative stress and inflammation in the adenohypophysis and normalized the activity of the HPA axis. Moreover, since SRD decreased serum melatonin levels, it is tempting to speculate that decreased endogenous melatonin levels could contribute to the pituitary dysfunction described herein. Previous studies support an important role of melatonin as a physiological regulator of the HPA axis in animals. In this line, early reports have shown an increase in corticosterone levels in young pinealectomized animals, that is lost in old T A B L E 1 Melatonin treatment does not affect biometric or biochemical parameters in control and SRD-treated rats Serum levels of glucose, triacylglycerides (TAG), and non-esterified fatty acids (NEFA) were determined in blood samples obtained from rats of each experimental group after three weeks of treatment. Average body weight of rats from each group was determined at the end of the experimental period. Data from three independent experiments performed in quadruplicate are shown as mean ± SEM; * P < 0.05, ** P < 0.01, *** P < 0,001 vs Control by ANOVA followed by Tukey's post hoc test.
F I G U R E 3
Melatonin treatment prevents the hyperactivation of the HPA axis induced after three weeks of SRD. A, A representative western blot of pituitary ACTH expression levels is shown below the densitometric analysis of blots from three independent experiments. Data are shown as mean ± SEM; *** P < 0.001 by ANOVA followed by Tukey's post hoc test. B, Plasma ACTH concentration was determined by a chemiluminiscent immunoassay, and (C) serum corticosterone levels by RIA. Data are shown as mean ± SEM, n = 10 animals per group; *** P < 0.001 by ANOVA followed by Tukey's post hoc test rats. 47 The involvement of an age-related decrease in melatonin production 48 in the higher corticosterone levels in old rats was suggested. In agreement, studies by Konakchieva et al 49, 50 demonstrated that melatonin administration for 5 days significantly reduces corticosterone secretion, attenuates the adrenocortical response to stress and increases HPA axis sensitivity to glucocorticoid suppression. Melatonin treatment decreases corticosterone levels in a mice model of chronic mild stress 51 and CRH, ACTH, corticosterone,and cytokine levels) in LPS-treated diabetic (STZ) rats. 52 More recently, Zhou et al have shown that melatonin or MT1/MT2 agonists (piromelatin or Neu-P11) decrease urinary corticosterone levels in high-fat fed rats under chronic stress or in diabetic rats. 53, 54 Several reports have demonstrated that increased nutrient availability generates oxidative stress as a result of ROS/RNS production from mitochondria and other sources that surpasses the antioxidant capacity of the tissue. 55, 56 Since SRDtreatment induced higher systemic levels of glucose, TAG and NEFA, it seems likely that an increased supply of nutrients could lead to the generation of oxidative stress, leading in turn to a pituitary dysfunction. In this regard, here we show an increase in lipid peroxidation along with the induction of catalase, and HO-1 in the pituitary gland from SRD-treated rats.
Oxidative stress has been associated with the generation of a low grade inflammatory state in the liver, the adipose tissue, and other tissues (for review see 58, 59 ). In particular, an increase in the number of adipose tissue macrophages has been linked to the expansion and inflammation of the adipose tissue, and to the occurrence of IR and type 2 diabetes (for review see 60 ). Activation of tissue macrophages in IR animals is not restricted to adipose tissue, as it has been also demonstrated in liver, skeletal muscle, and pancreatic islets. 60 In agreement, our results showed that administration of a SRD for three weeks provoked an increase in the number of pituitary macrophages, the induction of inflammasomeassociated proteins, and the expression levels of IL1-β in the pituitary gland. Although both M1 and M2-like macrophages have been detected in the anterior pituitary gland from control rats, 61 the increase in Il1b production in the adenohypophysis of SRD-treated rats suggests an imbalance in favor of pro-inflammatory macrophages.
Since both oxidative and inflammatory mechanisms could be involved in the development of the diet-induced pituitary dysfunction, we next wonder if a treatment with melatonin, a well-known antioxidant and anti-inflammatory molecule, could prevent the early dysregulation of the HPA axis induced by the administration of SRD. 32, 35 Several reports have indicated that melatonin administration could decrease glycemia, as well as serum cholesterol and TAG levels. [62] [63] [64] In our study, melatonin administered as a subcutaneous pellet throughout the duration of the experimental period, following a protocol previously validated, 37, 65, 66 did not affect these biochemical parameters. This discrepancy could be due to differences in administration routes, dosages and treatment duration. Nevertheless, melatonin treatment was effective in preventing the generation of oxidative stress in the adenohypophysis of SRD-treated rats (as shown by a decrease in lipoperoxide levels). As the induction of the antioxidant defense system could be triggered by ROS, this effect of melatonin could also account for the significant decrease in the levels of antioxidant enzymes. Macrophages can induce noninfectious inflammatory reactions through the recognition of danger-associated molecular patterns (DAMPs) released upon cellular injury. Binding of DAMPs to pattern-recognition receptors activates different intracellular pathways. Among them, activation of the NLP3-inflammasome pathway leads to the production of IL-1β and IL-18 [67] [68] [69] . Several studies have demonstrated the association between inflammasome activation and obesity-induced inflammation, insulin resistance, type 2 diabetes, [70] [71] [72] acute and chronic liver diseases, 73, 74 and diabetic nephropathies. 75 Our results on the activation of the NLP3-inflammasome are, to the best of our knowledge, the first report on the activation of this pathway in the pituitary gland of rats fed a SRD. Melatonin treatment not only prevented the increase in the number of macrophages but also blocked the induction of IL-1β and components of the NLP3-inflammasome in the adenohypophysis.
In agreement with our results, prevention of NLP3-inflammasome activation by melatonin has been demonstrated in inflammatory diseases and sepsis. 35, 76, 77 In harmony with these results, melatonin has been shown to favor the anti-inflammatory M2 phenotype over M1 in liver Kupffer cells, peritoneal macrophages, and splenocytes from stressed mice. 78 Our hypothesis on the involvement of oxidative/inflammatory effects in the pituitary dysfunction seems to be consistent with the melatonin-induced prevention of the increase in pituitary and systemic levels of ACTH and corticosterone in SRD-treated rats.
DAMPs generated within the pituitary gland as a consequence of the deleterious effects of ROS/RNS on cellular components, could attract and stimulate macrophages to produce cytokines that in turn impact on POMC production by corticotrophs. We thus speculate that a cross-talk could be established within the pituitary gland between activated tissue macrophages and corticotrophs. This hypothesis was supported by the results of experiments in which AtT-20 cells were incubated with conditioned media obtained from macrophages activated with LPS and mild supraphysiological glucose concentrations. In these experimental setting, we observed the stimulation of the NFκB pathway and the induction of POMC expression in AtT-20 cells. Similar results were obtained when these cells were incubated in the presence of IL-1β and other cytokines. 20, 24 Since melatonin treatment of macrophages prevented the stimulatory effect of conditioned media on POMC expression in AtT-20 corticotrophs, we suggest that by inhibiting the production of IL-1β (by blocking inflammasome activation) 79, 80 or other cytokines by local macrophages, as previously demonstrated in RAW264.7 cells, 81 melatonin could prevent the simulation of POMC/ACTH by pituitary corticotrophs in SRD-treated rats. An additional effect of melatonin in preventing ROS-dependent negative feed-back regulation of glucocorticoids on corticotroph POMC production as described by Asaba et al 82 could not be discarded. As previously indicated, melatonin effects on cellular physiology involves a variety of mechanisms. Some of them implicate its binding to specific receptors followed by activation of signal transduction pathways. However, melatonin exerts many of its antioxidant and anti-inflammatory effects by receptor-independent effects. 83, 84 89 Altogether, melatonin could affect HPA axis activity by exerting direct effects on pituitary pars distalis (receptor-independent) by interacting with MT1/MT2 receptors, by other mechanisms (eg, free radical scavenger, interaction with orphan nuclear receptors and molecules, as calmodulin) or by a combination of some or all the above. The complexity of the processes involved makes it difficult to determine the precise contribution of each mechanism to the effect of melatonin on the HPA axis activity. This issue will be explored in future studies. In summary, present results suggest that the diet-induced metabolic burden imposed on the anterior pituitary gland generates oxidative stress and inflammation. As a result of the deleterious effects associated with the production of ROS/ RNS, metabolites or damaged cellular components released to the extracellular medium signal the recruitment of circulating monocytes and activate tissue macrophages to produce cytokines. These effectors, in turn, stimulate the synthesis of POMC and ACTH by pituitary corticotrophs. By preventing the diet-induced HPA axis dysfunction, melatonin appears to be a suitable therapeutic option to attenuate the metabolic effects of glucocorticoid overproduction.
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